RecruitingNot ApplicableNCT06129760

Glioblastoma Remote Monitoring and Care - Research Protocol

Sponsor

Case Comprehensive Cancer Center

Enrollment

25 participants

Start Date

Apr 30, 2024

Study Type

INTERVENTIONAL

Conditions

Glioblastoma Venous Thromboembolism Seizures

Summary

The purpose of this research is to learn more about how what the Apple watch measures, in terms of walking data, heart rate, breathing rate, and sleep habits, relates to how participants feel. During the course of the treatment, the symptoms participants experience change, and whether the Apple watch can detect these changes. Ultimately, this knowledge is being used to design proactive tools and signatures that can predict complications or symptom changes before they happen.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

newly-diagnosed or recurrent glioblastoma undergoing treatment or active surveillance
at least 18 years of age at the time of study enrolment
Karnofsky Performance Status (KPS) ≥ 70% at time of study enrolment
able to comprehend informed consent form and provide informed consent
access to patient or caregiver's own Apple iPhone to interface with watch application for documentation of symptoms

Exclusion Criteria5

under 18 years of age at the time of study enrolment
inability to give informed consent due to aphasia or other language barrier
tattoos located on the skin of the wrist or forearm where the Apple Watch will be placed or other skin conditions preventing adequate sensor function
inability to tolerate Apple Watch for at least 12 hours per day on at least 50% of days in a four-week period
no access to patient or caregiver Apple iPhone to document symptoms

Interventions

DEVICEApple Watch

The wearable sensor device is the Apple Watch Series 6 or newer

Locations(1)

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06129760

Related Trials

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

NCT072256218 locations

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT061615191 location